Literature DB >> 21916576

The Wnt signaling pathway: implications for therapy in osteosarcoma.

Peter McQueen1, Samia Ghaffar, Yi Guo, Elyssa M Rubin, Xiaolin Zi, Bang H Hoang.   

Abstract

Osteosarcoma is the most common primary bone malignancy, with a high propensity for local invasion, early metastasis and relapse. While the molecular mechanisms behind osteosarcoma development and metastasis have not yet been fully elucidated, research has highlighted an important role for Wnt signaling. Several Wnt ligands, receptors and coreceptors are highly expressed in osteosarcoma cell lines, while Wnt inhibitors are downregulated. As a result, research has begun to identify mechanisms with which to inhibit Wnt signaling. The use of Wnt pathway inhibitors and the targeting of c-Met, a Wnt regulated proto-oncogene, may be two possible mechanisms for treatment of osteosarcoma. In addition, as the Wnt signaling pathway is a regulator of stem cells, reagents that function as Wnt inhibitors are currently under investigation as inhibitors of cancer stem cell proliferation. Research involving the Wnt signaling pathway and cancer stem cells holds promise for novel treatment options in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21916576     DOI: 10.1586/era.11.94

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  41 in total

1.  miR-155 promotes the growth of osteosarcoma in a HBP1-dependent mechanism.

Authors:  Xiaohui Sun; Xiaolin Geng; Jun Zhang; Hongxing Zhao; Ying Liu
Journal:  Mol Cell Biochem       Date:  2015-02-10       Impact factor: 3.396

2.  MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA.

Authors:  Zhi-cai Shi; Xue-rong Chu; Yun-gang Wu; Jin-hui Wu; Chun-wen Lu; Run-xiao Lü; Mu-chen Ding; Ning-fang Mao
Journal:  Tumour Biol       Date:  2015-06-03

3.  Wnt/β-Catenin Signaling Pathway Inhibitors: A Promising Cancer Therapy.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-07-09       Impact factor: 4.345

4.  Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.

Authors:  Yimin Ma; Yongxin Ren; Ethan Q Han; Huiwu Li; Di Chen; Joshua J Jacobs; Steven Gitelis; Regis J O'Keefe; Yrjö T Konttinen; Guoyong Yin; Tian-Fang Li
Journal:  Biochem Biophys Res Commun       Date:  2013-01-03       Impact factor: 3.575

5.  β-Catenin transcriptional activity is minimal in canine osteosarcoma and its targeted inhibition results in minimal changes to cell line behaviour.

Authors:  Caroline M Piskun; Timothy J Stein
Journal:  Vet Comp Oncol       Date:  2013-11-21       Impact factor: 2.613

6.  SDF-1/CXCR4 promotes F5M2 osteosarcoma cell migration by activating the Wnt/β-catenin signaling pathway.

Authors:  Yao Lu; Bin Hu; Guo-Feng Guan; Jie Chen; Chun-qiu Wang; Qiong Ma; Yan-Hua Wen; Xiu-Chun Qiu; Xiao-ping Zhang; Yong Zhou
Journal:  Med Oncol       Date:  2015-05-31       Impact factor: 3.064

7.  TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway.

Authors:  Ruhui Li; Jianguo Liu; Hong Wu; Lidi Liu; Lijun Wang; Shaokun Zhang
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

Review 8.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

9.  Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells.

Authors:  Huancai Liu; Yanchun Chen; Fenghua Zhou; Linlin Jie; Leidong Pu; Jie Ju; Fengjie Li; Zhigang Dai; Xin Wang; Shuanhu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

10.  Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms.

Authors:  Yinglong Zhang; Qiong Ma; Tao Liu; Shi Ke; Kuo Jiang; Yanhua Wen; Baoan Ma; Yong Zhou; Qingyu Fan; Xiuchun Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.